Automate Your Wheel Strategy on INCY
With Tiblio's Option Bot, you can configure your own wheel strategy including INCY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INCY
- Rev/Share 23.6519
- Book/Share 21.5158
- PB 3.9418
- Debt/Equity 0.0102
- CurrentRatio 2.8497
- ROIC 0.1792
- MktCap 16561369857.0
- FreeCF/Share 4.8778
- PFCF 17.5145
- PE 18.8784
- Debt/Assets 0.0073
- DivYield 0
- ROE 0.2409
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | INCY | Wells Fargo | Equal Weight | Overweight | -- | $89 | Aug. 6, 2025 |
| Initiation | INCY | Barclays | -- | Overweight | -- | $90 | Aug. 1, 2025 |
| Upgrade | INCY | Stifel | Hold | Buy | -- | $107 | June 16, 2025 |
| Downgrade | INCY | Guggenheim | Buy | Neutral | -- | -- | March 18, 2025 |
| Downgrade | INCY | William Blair | Outperform | Market Perform | -- | -- | March 18, 2025 |
| Initiation | INCY | UBS | -- | Neutral | -- | $77 | Dec. 17, 2024 |
| Initiation | INCY | Wolfe Research | -- | Outperform | -- | $84 | Oct. 1, 2024 |
| Downgrade | INCY | Truist | Buy | Hold | $83 | $74 | Sept. 18, 2024 |
News
INCY vs. ARGX: Which Stock Is the Better Value Option?
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Cramer reveals 5 undervalued stocks that are must-own heading into 2026
Published: September 24, 2025 by: Invezz
Sentiment: Positive
Famed investor Jim Cramer says investors shouldn't feel boxed out of the market as the benchmark S&P 500 index continued to print higher highs in the second half of 2025. “Sometimes, it can feel like there's nothing left to buy,” the former hedge fund manager agreed in a recent segment of Mad Money.
Read More
3 Potential Biotech Acquisition Targets
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.
Read More
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
Read More
INCY Announces New Late-Stage Data on Skin Disease Drug
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
Read More
Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (NASDAQ:INCY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants William Meury - CEO, President & Director Steven Stein - Executive VP & Chief Medical Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Hi. Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference.
Read More
Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (NASDAQ:INCY ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Emma Nealon Presentation Eric Schmidt Research Analyst Good morning, everyone. My name is Eric Schmidt.
Read More
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
Published: September 03, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #HSTRUTHS--Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa.
Read More
Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Read More
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.
Read More
Why Incyte (INCY) is a Top Value Stock for the Long-Term
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (NASDAQ:INCY ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Christiana Stamoulis - Executive VP & CFO Greg Shertzer - Senior Director of Investor Relations Mohamed Issa - Executive Vice President & Head of U.S. Oncology Pablo J. Cagnoni - President and Head of Research & Development William Meury - CEO, President & Director Conference Call Participants Brian Corey Abrahams - RBC Capital Markets, Research Division Conor Thomas MacKay - BMO Capital Markets Equity Research David Neil Lebowitz - Citigroup Inc., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Jay …
Read More
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Read More
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to a loss of $1.82 per share a year ago.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Read More
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
INCY or TECH: Which Is the Better Value Stock Right Now?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Incyte (INCY) or Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: July 02, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Read More
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
Read More
FDA Extends INCY's Application for Opzelura Label Expansion
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.
Read More
Incyte Says FDA Extended Review Period for Opzelura
Published: June 20, 2025 by: Market Watch
Sentiment: Negative
Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11.
Read More
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.
Read More
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Published: June 18, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). "Patients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without.
Read More
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
Read More
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025.
Read More
Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Read More
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Read More
About Incyte Corporation (INCY)
- IPO Date 1993-11-04
- Website https://www.incyte.com
- Industry Biotechnology
- CEO Herve Hoppenot
- Employees 2617